Published in Proc Natl Acad Sci U S A on November 24, 1998
Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (1999) 2.63
The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc Natl Acad Sci U S A (1999) 2.11
Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol (2000) 2.11
Genetic bottlenecks reduce population variation in an experimental RNA virus population. J Virol (2004) 2.02
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol (2006) 1.68
Estimation of population bottlenecks during systemic movement of tobacco mosaic virus in tobacco plants. J Virol (2003) 1.67
Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol (2001) 1.63
Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc Natl Acad Sci U S A (2001) 1.61
Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J Virol (2007) 1.50
Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol (2002) 1.50
Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases. J Virol (2007) 1.47
A stochastic version of corticosteriod pharmacogenomic model. AAPS J (2005) 1.42
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis (2003) 1.42
Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol (2004) 1.34
Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus. PLoS Pathog (2007) 1.31
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother (2003) 1.31
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Estimation of the effective number of founders that initiate an infection after aphid transmission of a multipartite plant virus. J Virol (2008) 1.24
Loss and recovery of genetic diversity in adapting populations of HIV. PLoS Genet (2014) 1.23
One is enough: in vivo effective population size is dose-dependent for a plant RNA virus. PLoS Pathog (2011) 1.23
Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol (2000) 1.21
Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol (2005) 1.18
Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J Virol (2001) 1.08
Structure and temporal dynamics of populations within wheat streak mosaic virus isolates. J Virol (2001) 1.08
Timing and order of transmission events is not directly reflected in a pathogen phylogeny. Mol Biol Evol (2014) 1.08
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol (2006) 1.06
Assessing the effects of human mixing patterns on human immunodeficiency virus-1 interhost phylogenetics through social network simulation. Genetics (2006) 1.06
Population genomics of intrapatient HIV-1 evolution. Elife (2015) 0.99
Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol (2005) 0.96
Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques. J Virol (2004) 0.94
CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects. J Transl Med (2004) 0.92
Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2007) 0.91
In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol (2006) 0.91
Quantifying selection against synonymous mutations in HIV-1 env evolution. J Virol (2013) 0.89
Genetic drift of HIV populations in culture. PLoS Genet (2009) 0.89
The evolutionary rate dynamically tracks changes in HIV-1 epidemics: application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. Epidemics (2009) 0.89
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother (2002) 0.87
Antiretroviral Drug Resistance in HIV-1. Curr Infect Dis Rep (1999) 0.87
The dynamics of HIV-1 adaptation in early infection. Genetics (2011) 0.87
Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol (2007) 0.85
Taking multiple infections of cells and recombination into account leads to small within-host effective-population-size estimates of HIV-1. PLoS One (2011) 0.83
Stochastic simulations suggest that HIV-1 survives close to its error threshold. PLoS Comput Biol (2012) 0.81
Phylogenetically resolving epidemiologic linkage. Proc Natl Acad Sci U S A (2016) 0.81
Stochastic effects are important in intrahost HIV evolution even when viral loads are high. Proc Natl Acad Sci U S A (2012) 0.79
Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG. AIDS Res Hum Retroviruses (2008) 0.78
Genetic Consequences of Antiviral Therapy on HIV-1. Comput Math Methods Med (2015) 0.78
Daily sampling of an HIV-1 patient with slowly progressing disease displays persistence of multiple env subpopulations consistent with neutrality. PLoS One (2011) 0.77
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. J Gen Virol (2013) 0.76
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. Retrovirology (2008) 0.75
Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution. Front Microbiol (2017) 0.75
Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
RNA virus mutations and fitness for survival. Annu Rev Microbiol (1997) 10.06
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol (1994) 6.76
Fitness of RNA virus decreased by Muller's ratchet. Nature (1990) 6.30
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc Natl Acad Sci U S A (1992) 4.22
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Basic concepts in RNA virus evolution. FASEB J (1996) 3.35
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol (1997) 3.29
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol (1992) 2.92
The origin of genetic information: viruses as models. Gene (1993) 2.90
Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci U S A (1997) 2.64
Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. J Virol (1993) 2.55
Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J Virol (1997) 2.47
Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques (1995) 2.36
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol (1995) 2.18
HIV-1: gambling on the evolution of drug resistance? Nat Med (1997) 1.54
Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J Virol (1994) 1.25
Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS (1996) 1.24
Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci U S A (1996) 1.22
Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis (1994) 1.18
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS (1997) 1.11
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J Virol (1998) 1.10
Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.07
Anti-CD4 therapy for AIDS suggested by mathematical models. Proc Biol Sci (1996) 1.05
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.90
Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus. Neth J Med (1989) 0.86
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
HIV-1 nomenclature proposal. Science (2000) 6.61
Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. J Clin Microbiol (2001) 6.40
Genome sequence of the plant pathogen Ralstonia solanacearum. Nature (2002) 6.23
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A (1992) 5.19
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J (1996) 3.92
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
[AIDS treatment in Africa: the risk of antiretroviral resistance]. Ned Tijdschr Geneeskd (2007) 3.15
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76
Antibody response in primary human immunodeficiency virus infection. Lancet (1987) 2.69
Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques (1993) 2.65
Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS (1997) 2.60
Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J Clin Microbiol (2003) 2.59
Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry (2001) 2.59
Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. Proc Natl Acad Sci U S A (1996) 2.57
Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci U S A (1993) 2.49
Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J Virol (1997) 2.47
Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques (1995) 2.36
Codistribution of collagen types IV and AB2 in basement membranes and mesangium of the kidney. an immunoferritin study of ultrathin frozen sections. J Cell Biol (1980) 2.30
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol (1994) 2.18
Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med (1989) 2.15
The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc Natl Acad Sci U S A (1999) 2.11
Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol (2000) 2.11
Laboratory-based surveillance in the molecular era: the TYPENED model, a joint data-sharing platform for clinical and public health laboratories. Euro Surveill (2013) 2.07
A superfamily of proteins involved in different secretion pathways in gram-negative bacteria: modular structure and specificity of the N-terminal domain. Mol Gen Genet (1994) 2.07
Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. Virology (1995) 2.07
Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J Virol (1991) 2.05
Intuitive hypertext-based molecular identification of micro-organisms. Lancet (1999) 2.01
Unified nomenclature for broadly conserved hrp genes of phytopathogenic bacteria. Mol Microbiol (1996) 1.95
Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet (2000) 1.94
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 1.93
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1997) 1.91
Characterization of Chlamydia trachomatis omp1 genotypes among sexually transmitted disease patients in Sweden. J Clin Microbiol (2001) 1.90
Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes. J Virol (1994) 1.88
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr (1999) 1.88
Estimating relative fitness in viral competition experiments. J Virol (2000) 1.87
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis (1993) 1.86
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother (1996) 1.85
Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS (1989) 1.83
Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med (2001) 1.82
Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol (2001) 1.79
PopA1, a protein which induces a hypersensitivity-like response on specific Petunia genotypes, is secreted via the Hrp pathway of Pseudomonas solanacearum. EMBO J (1994) 1.79
Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults. J Clin Microbiol (1997) 1.76
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 1.75
hrp genes of Pseudomonas solanacearum are homologous to pathogenicity determinants of animal pathogenic bacteria and are conserved among plant pathogenic bacteria. Mol Plant Microbe Interact (1993) 1.75
The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res (1995) 1.73
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol (1994) 1.72
Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses (1999) 1.69
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS (1988) 1.68
A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res Hum Retroviruses (1987) 1.67
Diagnostics of neisseriaceae and moraxellaceae by ribosomal DNA sequencing: ribosomal differentiation of medical microorganisms. J Clin Microbiol (2001) 1.66
Very-high-energy gamma rays from a distant quasar: how transparent is the universe? Science (2008) 1.65
Superiority of quantitative exercise thallium-201 variables in determining long-term prognosis in ambulatory patients with chest pain: a comparison with cardiac catheterization. J Am Coll Cardiol (1988) 1.65
Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. Ann Intern Med (1989) 1.62
Phylogeny of the Mycoplasma mycoides cluster as determined by sequence analysis of the 16S rRNA genes from the two rRNA operons. J Bacteriol (1996) 1.61
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis (2000) 1.60
A prospective evaluation of magnetic resonance cholangiopancreatography in patients with suspected bile duct obstruction. Gut (1998) 1.59
Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology (1993) 1.59
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J Clin Virol (2009) 1.58
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1993) 1.56
Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain. Mamm Genome (2000) 1.54
Evidence that the hrpB gene encodes a positive regulator of pathogenicity genes from Pseudomonas solanacearum. Mol Microbiol (1992) 1.54
Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci U S A (1996) 1.54
Most HIV-1 genetic subtypes have entered Sweden. AIDS (1997) 1.52
Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci U S A (1989) 1.48
Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery. N Engl J Med (1985) 1.47
Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol (2001) 1.45
Inotropic effect of nicardipine in patients with heart failure: assessment by left ventricular end-systolic pressure-volume analysis. J Am Coll Cardiol (1989) 1.44
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis (1995) 1.43
Efficacy of the latest generation of antibody assays for (early) detection of HIV 1 and HIV 2 infection. Vox Sang (1989) 1.43
Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients. FASEB J (1992) 1.41
[Vertical HIV-I-transmission. I. Risk and prevention in pregnancy]. Ned Tijdschr Geneeskd (1998) 1.40
Hydroxyurea interferes with antigen-dependent T-cell activation in vitro. Eur J Clin Invest (2000) 1.40